Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists
The DOI matches its Crossref record; 128 of the 132 references it cites were found in a registry or an index, and 4 are not checked yet.
Abstract
Vancomycin is a glycopeptide antibiotic that has been in clinical use for nearly 50 years as a penicillin alternative to treat penicillinase-producing strains of Staphylococcus aureus. It is one of the most widely used antibiotics in the United States for the treatment of serious gram-positive infections involving methicillin-resistant S. aureus (MRSA).1 Early use of vancomycin was associated with a number of adverse effects, including infusion-related toxicities, nephrotoxicity, and possible ototoxicity. Upon further investigation, it appears that the impurities in early formulations of vancomycin caused many of these adverse events.1–4 Its overall use was curtailed significantly with the development of semisynthetic penicillins (e.g., methicillin, oxacillin, nafcillin) that were considered less toxic.1–4 However, the steady rise in the number of MRSA infections since the early 1980s has once again brought vancomycin into the forefront as the primary treatment for infections caused by this organism....
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Principles and Practice of Infectious Diseases.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-818_5 · Cited by 12,025
(2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200405-644st · Cited by 5,877
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908
Self-citationHundahl, S. A., Fleming, I. D., Fremgen, A. M., & Menck, H. R. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981215)83:12<2638::aid-cncr31>3.0.co;2-1 · Cited by 1,836
Autoinduction and signal transduction in the regulation of staphylococcal virulence
Novick, R. P. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03526.x · Cited by 1,280 · cited 1×
“aureus that is responsible for orchestrating the expression of adherence factors, biofilm production, tolerance to vancomycin, and virulence factors.(66) The agr locus has been a subject of intense study because there appears to be a relationship between polymorphism in this gene cluster and patient response to vancom…”
BackgroundMartindale. The Extra Pharmacopoeia.
(1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-5-687_2 · Cited by 1,111
Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'
Drusano, G. L. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro862 · Cited by 930
Hidayat, L. K., Hsu, D. I., Quist, R., Shriner, K. A., & Wong-Beringer, A. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.19.2138 · Cited by 860 · cited 4×
“Hidayat et al.(53) prospectively investigated the efficacy and toxicity of adjusting vancomycin troughs to achieve an unbound concentration of at least four times the MIC.”
BackgroundInfluentialLevine, D. P. (2006) · Clinical Infectious Diseases · doi:10.1086/491709 · Cited by 838
Self-citationSakoulas, G., Moise-Broder, P. A., Schentag, J., Forrest, A., Moellering, R. C., & Eliopoulos, G. M. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.6.2398-2402.2004 · Cited by 836 · cited 2×
“Sakoulas et al.(52) reported a significant correlation between vancomycin susceptibilities and patient outcome.”
BackgroundSelf-citation
Research works printed but not linked: 5
- Virgincar, 2004, Glycopeptides (dalabavancin, oritavancin, teicoplanin, vancomycin), 181
- Cooper, 1986, The development of vancomycin, 1
- Geraci, 1977, Vancomycin, Mayo Clin Proc, 52, 631
- Boffi El Amari, 2004, High versus standard dose vancomycin for osteomyelitis, Scand J Infect Dis., 36, 712
- Dangerfield, 1960, Clinical use of vancomycin, Antimicrob Agents Chemother, 61, 428
Cited by
Items 401–500 of 1,002
Abbanat, D., Shang, W., Amsler, K. M., Santoro, C. M., Baum, E., Crespo‐Carbone, S. M., & Lynch, A. S. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.09.013 · Cited by 45
Asín‐Prieto, E., Isla, A., Canut, A., & Rodríguez‐Gascón, A. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2012.06.005 · Cited by 42
“Breakpoint divergences have been studied less extensively in Gram-positive bacteria, with the exception of glycopeptides [8] or the abovementioned penicillin and pneumococcal infection.”
BackgroundChua, K., & Howden, B. P. (2009) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e328331fbcd · Cited by 40
Marquis, K. A., DeGrado, J. R., Labonville, S. A., Kubiak, D. W., & Szumita, P. M. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015587900 · Cited by 37
“Consensus guidelines recommend vancomycin doses of 15 to 20 mg/kg, based on actual body weight, every 8 to 12 hours in patients with normal renal function.(4) Despite consensus guideline recommendations, dosing vancomycin remains a challenge at our institution; vancomycin is often initiated at a dosage of 1g every 12…”
BackgroundMethodInfluentialZelenitsky, S. A., Ariano, R. E., McCrae, M. L., & Vercaigne, L. M. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis458 · Cited by 37
Honda, H., Doern, C. D., Michael-Dunne, W., & Warren, D. K. (2011) · BMC Infectious Diseases · doi:10.1186/1471-2334-11-335 · Cited by 36
“However, there is no definitive human clinical data to support this recommendation [24].”
BackgroundElevated vancomycin trough is not associated with nephrotoxicity among inpatient veterans
Prabaker, K. K., Tran, T. P. ‐., Pratummas, T., Goetz, M. B., & Graber, C. J. (2011) · Journal of Hospital Medicine · doi:10.1002/jhm.946 · Cited by 37
“(typically 15-20 mg/L) for invasive MRSA infections and general avoidance of trough levels <10 mg/L.(14) The effect of higher trough levels on kidney function remains poorly understood, as does the mechanism of vancomycin-induced renal injury itself, though animal Received: January 3, 2011; Revised: May 9, 2011; Accep…”
BackgroundThe pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion
Waineo, M. F., Kuhn, T. C., & Brown, D. L. (2015) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12270 · Cited by 36
“If the MIC is≤1 mg/L, vancomycin therapy is warranted.(3,16) However, if the MIC is ≥2 mg/L, alternative therapeutic options should be explored based on clinical response, as it is unlikely that an AUC24/MIC >400 could be attained with conventional dosing.”
BackgroundMethodInfluentialJongsma, K., Joson, J., & Heidari, A. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt009 · Cited by 36
Guilhaumou, R., Marsot, A., Dupouey, J., Galambrun, C., Boulaméry, A., Coze, C., Simon, N., & André, N. (2016) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000318 · Cited by 36
“In 1997, Krivoy et al(12) recommended a dosage of 40 mg$kg21$d21, but target concentrations were considerably lower than those actually recommended.(2) In hematological malignancy patients treated with cyclosporine, recommended maintenance doses were especially different because of the decrease in vancomycin CL.”
BackgroundThe Impact of Pediatric-Specific Vancomycin Dosing Guidelines: A Quality Improvement Initiative
Miloslavsky, M., Galler, M. F., Moawad, I., Actis, J., Cummings, B., & Saleeby, C. M. E. (2017) · PEDIATRICS · doi:10.1542/peds.2016-2423 · Cited by 36
Jeon, N., Staley, B., Klinker, K. P., Hincapie‐Castillo, J. M., & Winterstein, A. G. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.02.023 · Cited by 39
Pharmacokinetic Assessment of Vancomycin Loading Dose in Critically Ill Patients
Álvarez, O., Plaza‐Plaza, J. C., Ramírez, M. M., Peralta, A. B., Amador, C. A., & Amador, R. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00280-17 · Cited by 40
“Serum levels of 10 and 20 g/ml have been linked to antibiotic resistance and nephrotoxicity, respectively (8, 16).”
BackgroundMethodInfluentialThe effect of neutropenia on the clinical pharmacokinetics of vancomycin in adults
Bury, D., ter Heine, R., van de Garde, E. M. W., Nijziel, M. R., Grouls, R. J. E., & Deenen, M. J. (2019) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-019-02657-6 · Cited by 36
Goldmann, O., Cern, A., Müsken, M., Rohde, M., Weiss, W., Barenholz, Y., & Medina, E. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.11.007 · Cited by 38
Chantadee, T., Santimaleeworagun, W., Phorom, Y., Chuenbarn, T., & Phaechamud, T. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.101615 · Cited by 36
Garzoni, C. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02892.x · Cited by 36
“Recently published guidelines suggest the following principles: (1) vancomycin minimal serum concentration should always be >10 lg/mL to prevent the development of resistance; (2) if the MIC is 1 lg/mL, the concentration should always exceed 15 lg/mL; (3) if the MIC is ≥2 lg/mL, alternative therapies should be conside…”
BackgroundLi, J., Li, K., Du, Y., Tang, X., Liu, C., Cao, S., Zhao, B., Huang, H. P., Zhao, H., Kong, W., et al. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s394366 · Cited by 35
“should be 15–20 μg/mL to achieve the treatment target and improve the clinical effectiveness.(42,43) The drug release rate of VAN/PLGA-MS prepared in this experiment was relatively stable from the second day.”
BackgroundEscobar, L., Andresen, M., Downey, P., Gai, M. N., Regueira, T., Bórquez, T., Lipman, J., & Roberts, J. A. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.03.009 · Cited by 35
Tsutsumi, L. S., Owusu, Y., Hurdle, J. G., & Sun, D. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026613666131113154753 · Cited by 42
“Notably, VAN has poor absorption in the GI tract and is not orally bioavailable; therefore, it can be used as an oral antibiotic for the treatment of CDI [71, 72].”
Nicasio, A. M., Bulitta, J. B., Lodise, T. P., D'Hondt, R. E., Kulawy, R., Louie, A., & Drusano, G. L. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05664-11 · Cited by 36
“and recent reports of rising nephrotoxicity (10, 22) (albeit poten-”
BackgroundCrew, P. E., Heintz, S. J., & Heintz, B. H. (2015) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp150051 · Cited by 35
Cánovas-Segura, B., Campos, M., Morales, A., Juárez, J. M., & Palacios, F. (2016) · Progress in Artificial Intelligence · doi:10.1007/s13748-016-0089-x · Cited by 38
“In particular, the levels of Vancomycin, an antibiotic used in some bloodstream infections, should be checked for certain patients, such as those who have an unstable renal function, both to prevent the development of resistant microorganisms and to avoid toxicity problems in the patient [67].”
BackgroundEconomou, C. J. P., Kielstein, J. T., Czock, D., Xie, J., Field, J., Richards, B., Tallott, M., Visser, A., König, C., Hafer, C., et al. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.03.001 · Cited by 35
“3 Dosing simulations Monte Carlo simulations (n=1000) were employed using Pmetrics to determine the probability of target attainment (PTA) of achieving the predefined AUC0-24/MIC target of 400 [15] and a target of AUC0-24>700 mg.”
MethodAndriguetti, N. B., Loss, L., Hahn, S. R., Pagnussat, L. R., Antunes, M. V., & Linden, R. (2018) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2018.12.023 · Cited by 35
“Therapeutic drug monitoring (TDM) of VCM aims o achieve through concentrations above 10 mg L−1 for uncompliated infections, requiring levels of up to 20 mg L−1 for more severe nfections [3].”
Kloprogge, F., Hill, L. F., Booth, J., Klein, N. J., Irwin, A., Dixon, G. L. J., & Standing, J. F. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00067-19 · Cited by 35
“Adult patients with a target AUC/MIC value of 400 mg·h/liter appeared to have a lower risk of treatment failure (16–18), and as free antibiotic concentrations drive the antibacterial effects, AUCfree/MIC of 200 mg·h/liter has consequently been reported as the target efficacy threshold (14).”
BackgroundInfluentialHashimoto, N., Kimura, T., Hamada, Y., Niwa, T., Hanai, Y., Chuma, M., Fujii, S., Matsumoto, K., Shigemi, A., Kawamura, H., et al. (2021) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2021.07.018 · Cited by 35
Kim, J., Walker, S. A. N., Iaboni, D. C., Walker, S. E., Elligsen, M., Dunn, M., Allen, V. G., & Simor, A. E. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01718-13 · Cited by 35
“Unfortunately, determination of the AUC for vancomycin in clinical settings is not feasible, and thus, vancomycin trough concentrations have been adopted as a surrogate marker for determining the likelihood of AUC target attainment where vancomycin trough concentrations of 15 to 20 mg/liter have been recommended for c…”
BackgroundMethodEmergency Pharmacist Impact on Health Care-Associated Pneumonia Empiric Therapy
DeFrates, S. R., Weant, K. A., Seamon, J. P., Shirakbari, A., & Baker, S. N. (2012) · Journal of Pharmacy Practice · doi:10.1177/0897190012451933 · Cited by 35
“Appropriate dosing was determined by guideline and drug-specific recommendations, and vancomycin was deemed appropriate if dosed between 15 and 25 mg/kg.(11) Time to appropriate antibiotic therapy was defined as the time when the final antibiotic in the regimen was charted as administered as this was the time point th…”
MethodUnderstanding pharmacokinetics/pharmacodynamics in managing neonatal sepsis
Lutsar, I., & Metsvaht, T. (2010) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e328337bb42 · Cited by 35
Vandecasteele, S. J., Bacquer, D. D., & Vriese, A. S. D. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir337 · Cited by 35
“5 g that is generally used for a single dose [10].”
BackgroundMethodInfluentialComputerized detection of adverse drug reactions in the medical intensive care unit
Kane‐Gill, S. L., Visweswaran, S., Saul, M. I., Wong, A.-K. I., Penrod, L. E., & Handler, S. M. (2011) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2011.04.005 · Cited by 39
“[33,54,55] Hypoglycemia has become more concerning in the MICU because of evidence supporting intensive insulin therapy that targets lower glucose concentrations and results in better patient outcomes.”
BackgroundSafety and Outcome of Pharmacy-Led Vancomycin Dosing and Monitoring
Momattin, H., Zogheib, M., Homoud, A. H., & Al‐Tawfiq, J. A. (2015) · Chemotherapy · doi:10.1159/000440607 · Cited by 35
Kullar, R., Davis, S. L., Kaye, K. S., Levine, D. P., Pogue, J. M., & Rybak, M. J. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1220 · Cited by 34
“5 mg/dl or 50% increase from baseline, whichever is greater) on 2 consecutive days in the absence of an alternative explanation.(20) Any of the following was considered to represent an elevated creatine kinase (CK) level: unexplained CK elevation greater than 2000 U/L (10 times the upper limit of normal), unexplained…”
BackgroundSelf-citationShort term impact of guidelines on vancomycin dosing and therapeutic drug monitoring
Swartling, M., Gupta, R., Dudas, V., & Guglielmo, B. J. (2012) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-012-9614-6 · Cited by 34
“The recommended minimum trough concentration is 10 mg/L for uncomplicated infections, while a trough of 15–20 mg/L is recommended for more complicated infections, including osteomyelitis and endocarditis [5].”
BackgroundVardakas, K. Z., Mavros, M. N., Roussos, N. S., & Falagas, M. E. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2011.12.011 · Cited by 34
Machado, A. S., de Oliveira, M. S., Sanches, C., da Silva, C. V., Gomez, D. D. S., Gemperli, R., Santos, S. R. C. J., & Levin, A. S. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.06.008 · Cited by 35
Sharma, R., & Hammerschlag, M. R. (2019) · Current Infectious Disease Reports · doi:10.1007/s11908-019-0695-4 · Cited by 38
Dinu, V. T., Lu, Y., Weston, N., Lithgo, R. M., Coupe, H., Channell, G. A., Adams, G. G., Torcello‐Gómez, A., Sabater, C., Mackie, A. R., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-57776-3 · Cited by 39
Use of Machine Learning for Dosage Individualization of Vancomycin in Neonates
Tang, B., Zhang, J., Allegaert, K., Hao, G., Yao, B., Leroux, S., Thomson, A. H., Yu, Z. Y., Gao, F., Zheng, Y., et al. (2023) · Clinical Pharmacokinetics · doi:10.1007/s40262-023-01265-z · Cited by 36
“However, both steady-state trough concentrations ( C 0 ) and steady-state area-under-curve (AUC 0–24 ) have been used as surrogate markers of response and toxicity, so these play important roles in individualizing vancomycin therapy [3, 4].”
MethodSpadaro, S., Berselli, A., Fogagnolo, A., Capuzzo, M., Ragazzi, R., Marangoni, E., Bertacchini, S., & Volta, C. A. (2015) · BMC Anesthesiology · doi:10.1186/s12871-015-0065-1 · Cited by 34
“In this connection it should be pointed out that the AUC/MIC in both groups (group A: 468 ± 79 and group B: 490 ± 84, respectively) was in the desired range (>400) [5] at the first VSC determination (Table 2).”
BackgroundMethodInfluentialMarinho, D. S., Huf, G., Ferreira, B. L., Castro, H. C., Rodrigues, C. R., de Sousa, V. P., & Cabral, L. M. (2011) · BMC Research Notes · doi:10.1186/1756-0500-4-236 · Cited by 34
“This fact reinforces the importance of laboratory monitoring vancomycin use [13].”
BackgroundVancomycin dosage in overweight and obese children
Miller, M. M., Miller, J. L., Hagemann, T. M., Harrison, D. L., Chávez‐Bueno, S., & Johnson, P. N. (2011) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp110107 · Cited by 35
Elyasi, S., & Khalili, H. (2016) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-016-2063-8 · Cited by 34
“For the last several decades, vancomycin has been the mainstay of therapy for methicillin-resistant Staphylococcus aureus (MRSA) infections in most of cases, and still remains the firstline choice [1–11].”
BackgroundInfluentialPereira, M. R., Rana, M. M., & Practice, T. A. I. C. O. (2019) · Clinical Transplantation · doi:10.1111/ctr.13611 · Cited by 35
Therapeutic Drug Monitoring of Antibiotics: Defining the Therapeutic Range.
Abdul-Aziz, M. H., Brady, K., Cotta, M. O., & Roberts, J. A. (2022) · PubMed · doi:10.1097/ftd.0000000000000940 · Cited by 48
Hall, N. M., Brown, M. L., Edwards, W. S., Oster, R. A., Cordell, W., & Stripling, J. T. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae002 · Cited by 33
“AUC/MIC is the pharmacokinetic parameter best correlated with the antibacterial activity of vancomycin, and AUC-guided dosing and monitoring has been shown to reduce risk of VA-AKI and improve patient outcomes [8–10].”
BackgroundMenon, R., Bhattarai, S. K., Crossette, E. M., Prince, A., Olle, B., Silber, J. L., Bucci, V., Faith, J. J., & Norman, J. M. (2025) · Nature Medicine · doi:10.1038/s41591-024-03337-4 · Cited by 42
“This observation is consistent with vancomycin susceptibility of the VE303 strains, as stool vancomycin concentrations after QID dosing were greater than the minimum inhibitory concentration values of VE303 strains 21 (Extended Data Table 1).”
Contreiras, C., Legal, M., Lau, T. T. Y., Thalakada, R., Shalansky, S. J., & Ensom, M. H. H. (2014) · The Canadian Journal of Hospital Pharmacy · doi:10.4212/cjhp.v67i2.1340 · Cited by 33
“achieve this AUC/MIC for organisms with MIC of 1 mg/L or below.(1) Given that higher trough levels are becoming more”
BackgroundInfluentialSafety of topical vancomycin powder in neurosurgery
Abdullah, K., Chen, H., & Lucas, T. (2016) · Surgical Neurology International · doi:10.4103/2152-7806.195227 · Cited by 35
Li, X., Sun, S., Ling, X. W., Chen, K., Wang, Q., & Zhao, Z. (2017) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-017-2313-4 · Cited by 33
Population Pharmacokinetics of Vancomycin in Chinese ICU Neonates: Initial Dosage Recommendations
Li, Z., Liu, Y., Jiao, Z., Qiu, G., Huang, J., Xiao, Y., Wu, S., Wang, C., Hu, W., & Sun, H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00603 · Cited by 33
“The current guidelines or consensus for therapeutic drug management (TDM) of vancomycin in the United States (Rybak et al., 2009), Japan (Matsumoto et al., 2013) and China (Ye et al., 2016) recommends that trough concentrations should be collected at regular intervals in clinical settings.”
BackgroundInfluentialPopulation pharmacokinetic analysis of vancomycin in pediatric continuous renal replacement therapy
Moffett, B. S., Morris, J. L., Muñoz, F. M., & Akcan‐Arikan, A. (2019) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-019-02664-7 · Cited by 33
The Effect of Paraproteins and Rheumatoid Factor on Four Commercial Immunoassays for Vancomycin
LeGatt, D. F., Blakney, G. B., Higgins, T., Schnabl, K. L., Shalapay, C. E., Dias, V. C., & Wesenberg, J. C. (2012) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e318257335f · Cited by 33
Reversible detection of vancomycin using peptide-functionalized cantilever array sensor
Bai, X., Lu, B., Chen, X., Zhang, B., & Tang, J. (2014) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2014.06.024 · Cited by 33
Fu, J., Ye, X., Cha, C., & Chen, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058240 · Cited by 33
“1 mg/ml as supported by consensus guidelines [81].”
MethodMizuno, T., Mizokami, F., Fukami, K., Kato, R., Shibasaki, M., Nagamatsu, T., & Furuta, K. (2013) · Clinical Interventions in Aging · doi:10.2147/cia.s52259 · Cited by 35
Loc-Carrillo, C., Wang, C., Canden, A., Burr, M., & Agarwal, J. P. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160187 · Cited by 33
McQueen, K. E., & Clark, D. (2016) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-21.4.332 · Cited by 33
Grupper, M., & Nicolau, D. P. (2017) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000356 · Cited by 34
“Usage guidelines for this compound, which is in clinical practice for over 50 years, have been published [24–25], and advocate for TBW-based dosing [24].”
MethodCardone, K. E., Lodise, T. P., Patel, N., Hoy, C. D., Meola, S., Manley, H. J., Drusano, G. L., & Grabe, D. W. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.08510910 · Cited by 32
Prospective evaluation of vancomycin pharmacokinetics in a heterogeneous critically ill population
Turner, R. B., Kojiro, K., Won, R., Chang, E., Chan, D., & Elbarbry, F. (2018) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2018.06.022 · Cited by 33
Hornak, J. P., Anjum, S. H., & Reynoso, D. (2019) · Therapeutic Advances in Infectious Disease · doi:10.1177/2049936119886504 · Cited by 39
Prosthetic valve endocarditis: state of the heart
Nagpal, A., Sohail, M. R., & Steckelberg, J. M. (2012) · Clinical Investigation · doi:10.4155/cli.12.70 · Cited by 31
Walkty, A. J., Adam, H. J., Laverdière, M., Karlowsky, J. A., Hoban, D. J., & Zhanel, G. G. (2011) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2010.10.032 · Cited by 32
The use and risks of antibiotics in critically ill patients
Denny, K. J., Cotta, M. O., Parker, S. L., Roberts, J. A., & Lipman, J. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1164690 · Cited by 33
“[27] One means of overcoming the lag time in achieving target vancomycin concentrations, and hence minimizing risk of treatment failure, may be through the use of loading doses.[28,29]”
BackgroundAssessment of Vancomycin Pharmacokinetics and Dose Regimen Optimisation in Preterm Neonates
Mulubwa, M., Griesel, H. A., Mugabo, P., Dippenaar, R., & van Wyk, L. (2020) · Drugs in R&D · doi:10.1007/s40268-020-00302-7 · Cited by 33
Lv, C., Lu, J., Chen, M., Zhang, R., Li, Q., Chen, Y., & Liu, T. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13206 · Cited by 32
Assessing the accuracy of two Bayesian forecasting programs in estimating vancomycin drug exposure
Shingde, R., Reuter, S. E., Graham, G. G., Carland, J. E., Williams, K. M., Day, R. O., & STOCKER, S. L. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa320 · Cited by 36
Resztak, M., Sobiak, J., & Czyrski, A. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13121991 · Cited by 32
“However, the administration of VAN every 12 h with dose 15 mg/kg is unlikely to produce the concentrations of 15–20 mg/L [127,129].”
Pharmacotherapy in the Critically Ill Obese Patient
Medico, C. J., & Walsh, P. (2010) · Critical Care Clinics · doi:10.1016/j.ccc.2010.07.003 · Cited by 31
Salem, A. H., Zhanel, G. G., Ibrahim, S. A.-S., & Noreddin, A. M. (2013) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12195 · Cited by 32
“It is also worth mentioning that although an in vitro study has suggested an AUC/MIC target level of 1113 for the pharmacodynamic efficacy of vancomycin against MRSA,(60) we choose to use the target level of 400 advocated in the recent vancomycin therapy guidelines.(42,61)”
MethodResultCulos, K. A. A., Cannon, J. P., & Grim, S. A. (2011) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31821109ec · Cited by 31
“aureus isolates with MIC $ 2 mg mL(21).(41) Currently, vancomycin is still the first-line agent for most MRSA infections.”
BackgroundInfluentialCurrent pharmacotherapy options for osteomyelitis: convergences, divergences and lessons to be drawn
Senneville, É., & Nguyen, S. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.780596 · Cited by 31
“Its bactericidal effect depends on several bacterial factors including polymorphism and function in the accessory gene (agr) regulator pathway, which cannot be characterized in routine practice [20].”
BackgroundInfluence of Renal Function Estimation on Pharmacokinetic Modeling of Vancomycin in Elderly Patients
Glatard, A., Bourguignon, L., Jelliffe, R. W., Maire, P. H., Neely, M. N., & Goutelle, S. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04132-14 · Cited by 32
“More recently, it has been suggested that AUC should be used as a target criterion in place of trough level for vancomycin therapeutic drug monitoring, because it better correlates with the drug efficacy (24, 25).”
BackgroundChan, J. D., Pham, T. N., Wong, J., Hessel, M., Cuschieri, J., Neff, M. J., & Dellit, T. H. (2011) · Journal of Intensive Care Medicine · doi:10.1177/0885066610392893 · Cited by 31
“The accumulated evidence has prompted recent consensus guideline to recommend weight-based dosing to target vancomycin trough levels of 15 to 20 mg/mL in the treatment of MRSA pneumonia and severe infections.(1,18) Previous investigations have identified a potential relationship between vancomycin PK indices (24-hour…”
BackgroundJoson, J., Grover, C. A., Downer, C., Pujar, T., & Heidari, A. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr234 · Cited by 31
Principles of Anti-Infective Therapy
Eliopoulos, G. M. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1604-7.00287-6 · Cited by 31
The pharmacokinetics of vancomycin during the initial loading dose in patients with septic shock
Katip, W., Jaruratanasirikul, S., Pattharachayakul, S., Wongpoowarak, W., Jitsurong, A., & Lucksiri, A. (2016) · Infection and Drug Resistance · doi:10.2147/idr.s121513 · Cited by 31
Ji, X., Ji, S., He, X.-R., Zhu, X., Chen, R., & Lu, W. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.57 · Cited by 31
Vancomycin in peritoneal dialysis: Clinical pharmacology considerations in therapy
Lam, E., Lien, Y. T., Kraft, W., Piraino, B., Vozmediano, V., Schmidt, S., & Zhang, J. (2020) · Peritoneal Dialysis International · doi:10.1177/0896860819889774 · Cited by 31
“(2, 3) An initial distribution half-life ranging from 30 minutes to 1 88 hour followed by a mean terminal elimination half-life ranging from 6-12 hours were determined 89 following intravenous dosing in patients with normal renal function.(3) Metabolism is negligible and 90 elimination occurs primarily through glomeru…”
BackgroundPenicillin skin testing in cardiac surgery.
Cook, D. J., Barbara, D. W., Singh, K. E., & Dearani, J. A. (2014) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2014.01.019 · Cited by 30
An Evaluation of Vancomycin Dosing for Complicated Infections in Pediatric Patients
Durham, S. H., Simmons, M. L., Mulherin, D. W., & Foland, J. A. (2015) · Hospital Pediatrics · doi:10.1542/hpeds.2014-0081 · Cited by 30
Tattevin, P., Saleh‐Mghir, A., Davido, B., Ghout, I., Massias, L., de la Maria, C. G., Miró, J. M., Perronne, C., Laurent, F. J., & Crémieux, A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01669-12 · Cited by 32
“Although these pharmacokinetic parameters are in accordance with past recommendations (25), more recent guidelines recommend targeting trough serum concentrations of VAN between 15 and 20 g/ml for the treatment of severe infectious diseases in humans (26).”
BackgroundMethodCrompton, J. A., North, D. S., Yoon, M., Steenbergen, J. N., Lamp, K. C., & Forrest, G. N. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq200 · Cited by 30
The standard one gram dose of vancomycin is not adequate prophylaxis for MRSA.
Catanzano, A. A., Phillips, M., Dubrovskaya, Y., Hutzler, L. H., & Bosco, J. A. (2014) · PubMed · Cited by 37
Periprosthetic Joint Infection of the Hip and Knee
Springer, B. D., & Parvizi, J. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7928-4 · Cited by 34
Broussou, D. C., Lacroix, M. Z., Toutain, P., Woehrlé, F., Garch, F. E., Bousquet‐mélou, A., & Ferran, A. A. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00572 · Cited by 41
“…exposure to different dosage regimens of a susceptible strain of S. aureus with MICs of 1 µg/mL for amikacin and vancomycin led to equal or higher values of the PK/PD indices than those classically expected to obtain drug efficacy (Zelenitsky et al., 2003; Rybak et al., 2009; Song et al., 2015).”
BackgroundMethodHeffernan, A. J., Germano, A. J. M. M. E. T., Sime, F. B., Roberts, J. A., & Kimura, E. M. (2019) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-019-02694-1 · Cited by 30
Emergent Renal Dysfunction with Colistin Pharmacotherapy
Collins, J. M., Haynes, K., & Gallagher, J. C. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1271 · Cited by 30
Leu, W.-J., Liu, Y.-C., Wang, H.-W., Chien, H.-Y., Liu, H.-P., & Lin, Y.-M. (2012) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2012.07.005 · Cited by 30
Taylor, M. E., & Allon, M. (2010) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2010.03.016 · Cited by 30
Transplacental passage of vancomycin
Towers, C. V., & Weitz, B. W. (2017) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2017.1306049 · Cited by 30
Seki, M., Yabuno, Tomono, Miyawaki, & Miwa, Y. (2012) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s37528 · Cited by 30
“5 mg/dL or 50% from baseline.(6,10) Hepatotoxicity was defined as AST or ALT that was three-fold the upper limit of normal (ULN; AST: 13–33 IU/L, ALT: 8–42 IU/L).”
BackgroundKam, K. Q., Chen, T., Kadri, S. S., Lawandi, A., Yek, C., Walker, M., Warner, S., Fram, D., Chen, H.-C., Shappell, C. N., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciae591 · Cited by 29
Diep, C., Meng, L., Pourali, S., Hitchcock, M. M., Alegria, W., Swayngim, R., Ran, R., Banaei, N., Deresinski, S. C., & Holubar, M. K. (2021) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxab296 · Cited by 31
Sung, J. Y., Lee, J., Choi, E. H., & Lee, H. J. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.05.018 · Cited by 29
Clinical activity of anti-Gram-positive agents against methicillin-resistant Staphylococcus aureus
Gould, I. M. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr073 · Cited by 34
Moise, P. A., Forrest, A., Bayer, A. S., Xiong, Y.-Q., Yeaman, M. R., & Sakoulas, G. (2009) · The Journal of Infectious Diseases · doi:10.1086/649429 · Cited by 29
“aureus infection [23].”
Clinical Pharmacokinetics of Vancomycin in Critically Ill Children
Sridharan, K., Daylami, A. A., Ajjawi, R., Ajooz, H. A. A., & Veeramuthu, S. (2019) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-019-00568-6 · Cited by 32
Metadata
- Authors
- Rybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R., Craig, W., Billeter, M., Dalovisio, J. R., & Levine, D. P.
- Affiliations
- Eugene Applebaum College of Pharmacy and Health Sciences (US)
- Albany Medical Center Hospital (US)
- University of Minnesota (US)
- Beth Israel Deaconess Medical Center (US)
- University of Wisconsin–Madison (US)
- New Orleans, LA
- Ochsner Health System (US)
- Division of General Internal Medicine, WSU
- Corresponding author
- Rybak, Michael
- Venue
- American Journal of Health-System Pharmacy
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-01-01
- Volume
- 66
- Issue
- 1
- Pages
- 82-98
- ISSN
- 1079-2082 (ISSN-L)
- 1535-2900
- OpenAlex
- W2133120422
- Semantic Scholar
- f97f86b0eb5acbf0d7b5f8d4197a9e67f28c94ab
- Cited by
- 1,795
- References
- 130
- Citations by year
- 2026: 41 · 2025: 63 · 2024: 60 · 2023: 72 · 2022: 94 · 2021: 110 · 2020: 135 · 2019: 129 · 2018: 123 · 2017: 113 · 2016: 104 · 2015: 120 · 2014: 122 · 2013: 119 · 2012: 120
- FWCI
- 61.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Health-System Pharmacy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Keywords
- vancomycin, therapeutic drug monitoring, glycopeptides, methicillin-resistant Staphylococcus aureus, MRSA infection, Gram-positive bacterial infections, nephrotoxicity, ototoxicity, infusion-related toxicity, adverse drug reactions, pharmacokinetics, pharmacodynamics
- MeSH terms
- Adult, Anti-Bacterial Agents, Humans, Vancomycin, Drug Monitoring, Gram-Positive Bacterial Infections, Practice Guidelines as Topic, Vancomycin Resistance, Methicillin-Resistant Staphylococcus aureus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.